ClinicalTrials.gg
Not yet recruitingNCT07712757Updated Jul 17, 2026

Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma

A Phase 3 interventional study of Safusidenib and Placebo in Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation, Astrocytoma IDH Mutant Grade 2 and Oligodendroglioma, sponsored by Nuvation Bio Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Nuvation Bio Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study comparing the efficacy and safety of safusidenib versus placebo in participants with residual or recurrent Grade 2 glioma (oligodendroglioma or astrocytoma) with an IDH1 mutation who have undergone surgery as their only treatment and are not in need of immediate chemotherapy or radiotherapy.

02

Conditions studied

  • Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation
  • Astrocytoma IDH Mutant Grade 2
  • Oligodendroglioma
  • Oligodendroglioma IDH-mutant and 1p/19q-codeleted
  • IDH-mutant Gliomas

Keywords

  • safusidenib
  • IDH1-mutant Glioma
03

In context

Astrocytoma

688 studies on the registry are indexed under Astrocytoma; 80 are open to participants now.

This study's planned enrollment of 140 is above the median of 31 across 531 interventional studies indexed under Astrocytoma.

Browse Astrocytoma studies →

Lead sponsor

Nuvation Bio Inc. is the lead sponsor of 19 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Expected survival of ≥12 months.
  • At least 1 prior surgery for glioma (, sub-total resection, or gross total resection), with the most recent surgery having occurred at least 90 days (or at least 28 days if biopsy only and postoperative changes have resolved per BICR) and no longer than 5 years before the date of randomization
  • Have not had any other prior anticancer therapy, including chemotherapy and radiotherapy; and are not in need of immediate chemotherapy or radiotherapy in the opinion of the Investigator.
  • confirmed Grade 2, IDH1-mutant oligodendroglioma or astrocytoma according to World Health Organization Central Nervous System 2021 classification criteria per Investigator assessment.
  • IDH1 mutation (R132H/C/G/S/L), identified by polymerase chain reaction, next-generation sequencing (NGS), or immunohistochemistry; and confirmed 1p19q codeletion status by fluorescence in situ hybridization, NGS, or array comparative genomic hybridization.
  • Residual or recurrent, measurable, non-enhancing disease, as confirmed by BICR per RANO 2.0, assessed at Screening.
  • Adequate hematologic and organ functions

Key Exclusion Criteria:

  • Any prior anticancer therapy other than surgery (biopsy, sub-total, or gross total resection) for treatment of glioma, including chemotherapy, therapies, prior therapies targeting IDH1 or IDH2, anti-angiogenic therapies, tumor-treating fields, or radiotherapy.
  • High-risk features as assessed by the Investigator, including brainstem or spinal cord involvement either as primary location or by significant tumor extension, functional or neurocognitive deficits due to the tumor (deficits resulting from surgery are allowed), or uncontrolled seizures (defined as persistent seizures interfering with ability to comply with protocol requirements).
  • Evidence of .
  • Use of therapeutic doses of for signs/symptoms of glioma. Participants taking physiologic doses (defined as equivalent of \<1.5 mg of dexamethasone equivalent) for medical conditions not related to glioma will be permitted.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Safusidenib

    Safusidenib 250 mg BID

    Drug: Safusidenib

  • Placebo comparator
    Placebo

    Placebo BID

    Drug: Placebo

Interventions

  • Safusidenib administered twice daily as a single agent dosed orally on Days 1 through 28 of a 28-day cycle. Participants may continue treatment until disease progression or another reason for discontinuation occurs.

  • DrugPlacebo

    Placebo administered twice daily as a single agent dosed orally on Days 1 through 28 of a 28-day cycle. Participants may continue treatment with placebo until disease progression or another reason for discontinuation occurs.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) per modified Response Assessment in Neuro-Oncology (RANO) 2.0

    PFS, defined as time from date of randomization to the date of the first occurrence of radiographic disease progression per modified RANO 2.0 assessed by BICR or death from any cause, whichever occurs earlier

    Time frame: From the date of randomization until the date of first documented disease progression, approximately 30 months

Secondary outcomes

  1. Objective Response Rate (ORR) assessed by BICR per modified RANO 2.0

    ORR, defined as the proportion of participants with the confirmed best overall response of Complete Response (CR), Partial Response (PR), or Minor Response (MR) per modified RANO 2.0 assessed by BICR

    Time frame: From the date of randomization until the date of first documented disease progression, approximately 30 months

  2. Time to Next Intervention (TTNI)

    TTNI, defined as the time from randomization to the initiation of first subsequent anticancer therapy or death from any cause, whichever occurs earlier.

    Time frame: From the date of randomization until the date of the start of another anticancer treatment or date of death, approximately 30 months

  3. PFS assessed by the Investigator per modified RANO 2.0

    PFS, defined as the time from date of randomization to the date of the first occurrence of radiographic disease progression per modified RANO 2.0 assessed by the Investigator or death from any cause, whichever occurs earlier

    Time frame: From the date of randomization until the date of first documented disease progression, approximately 30 months

  4. ORR assessed by the Investigator per modified RANO 2.0

    ORR, defined as the proportion of participants with the confirmed best overall response of CR, PR, and MR per modified RANO 2.0 as assessed by the investigator.

    Time frame: From the date of randomization until the date of the first documented disease progression, approximately 30 months

  5. Duration of Response (DOR) assessed by BICR and by the Investigator per modified RANO 2.0

    DOR, the time from the first documentation of objective response (CR, PR, or MR) to the date of the first occurrence of radiographic disease progression per modified RANO 2.0 or death from any cause, whichever occurs earlier, as assessed by BICR and by the Investigator.

    Time frame: From the date of randomization until the date of first documented disease progression, approximately 30 months

  6. Time to Response (TTR) assessed by BICR and by the Investigator per modified RANO 2.0

    TTR, defined as the time from randomization to the first documentation of objective response (CR, PR, or MR) per modified RANO 2.0 assessed by BICR and by the Investigator.

    Time frame: From randomization to the first documentation of objective response (CR, PR, or MR), approximately 30 months

  7. Disease Control Rate (DCR) assessed by BICR and by the Investigator per modified RANO 2.0

    DCR, defined as the proportion of participants with a best overall response of CR, PR, MR, or stable disease (SD) per modified RANO 2.0, as assessed by BICR and by the Investigator

    Time frame: From the date of randomization until the date of first documented disease progression, approximately 30 months

  8. Tumor Growth Rate (TGR) by volume assessed by BICR

    TGR defined as the percentage change in tumor volume by unit of time, assessed by BICR

    Time frame: From historical scans through the final scan in the study, approximately 30 months

  9. Overall Survival (OS)

    OS, defined as the time from randomization to death from any cause

    Time frame: From the date of randomization until the date of death, approximately 30 months

  10. Safety and tolerability

    The safety and tolerability of safusidenib compared with placebo evaluated based on AEs graded by NCI-CTCAE version 5.0, laboratory abnormalities as graded by NCI-CTCAE version 5.0, vital signs, physical examinations, and ECGs

    Time frame: From the first dose of study drug until 30 days after treatment discontinuation, approximately 30 months

  11. Safusidenib PK Profile

    Characterize the safusidenib concentrations

    Time frame: From the first dose of study drug through approximately 16 weeks

  12. Health-Related Quality of Life

    Evaluate health-related quality of life (HRQoL) with safusidenib compared with placebo assessed by the Functional Assessment of Cancer Therapy-Brain (FACT-Br) questionnaire scores.

    Time frame: From the first dose of study drug to treatment discontinuation, approximately 30 months

  13. Health-Related Quality of Life

    Evaluate health-related quality of life (HRQoL) with safusidenib compared with placebo assessed by the Quality of Life in Epilepsy (QOLIE-10-P) scores.

    Time frame: From the first dose of study drug to treatment discontinuation, approximately 30 months

  14. Health-Related Quality of Life

    Evaluate health-related quality of life (HRQoL) with safusidenib compared with placebo assessed by the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire scores.

    Time frame: From the first dose of study drug to treatment discontinuation, approximately 30 months

  15. Seizure Activity

    Evaluate seizure frequencies and severity including type of seizure, seizure-related AEs, and changes in anti-epileptic medications in participants receiving safusidenib compared with placebo

    Time frame: From the date of randomization until the date of first documented disease progression, approximately 30 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2027; primary completion for May 2029, 26 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2026
First posted
Jul 17, 2026
StartEst.
Mar 2027
Primary completionEst.
May 2029
CompletionEst.
Mar 2032
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07712757
Lead sponsor
Nuvation Bio Inc.
Responsible party
Sponsor
First posted
Jul 17, 2026
Start date
Mar 2027 (estimated)
Primary completion
May 2029 (estimated)
Completion
Mar 2032 (estimated)
Last update
Jul 17, 2026

Study contacts

Clinical Trials at Nuvation Bio
Contact
ClinicalTrials@nuvationbio.com
332-208-6102

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Safusidenib

Start the discussion